Det er tungt Ä fÄ presset ned kursen for tiden ser jeg. FOMO tÄka ligger vel tungt
Burde nok brukt google translate her ja 
1 Like
Dessverre er svĂŠrt lav interesse for selskapet, noe som gjenspeiles I omsetning.
Virker som det er mye nigerianske prinser investert i pho for tiden.
Never change 
1337
Kan tyde pĂ„ at eliten er pĂ„ tur innâŠ
Eller kanskje word spelling and grammar check, min beste venn nÄr jeg skriver pÄ outlandish 
Han skal fÄ jobbe for lÞnna 8 Mai, selveste DS.
Vis ikke er det fare for at man fÄr igjen litt veksel, pÄ den berÞmte 50-lappen 
Hadde litt dÄrlig tid sÄ tok det pÄ direkte. Merker meg at det ofte tyr til latterliggjÞring pÄ forumet, det er hÞyst beklagelig. NÄr en googler latterliggjÞring fÄr en opp;
LatterliggjÞring** skjer gjennom overbÊrenhet, hÄning, barnlig opptreden eller ved Ä bli sammenliknet med dyreverdenen, jevnfÞrt med Ä vÊre dum som en sau eller dum som ei gÄs.
Ikke noe godt personlighets trekk.
NĂ„r moderator tyr til det samme er det utilgivelig og kan Ăždelegge forumet, eller er det slik det skal vĂŠre i slike Trump tider?
1 Like
Mulig du fÄr rett eller at han vil bruke mye tid pÄ Cevira etter Ä ha lest Asieris sin annual .report for 2024
Hadde vĂŠrt fint, om de kunne dele litt optimisme rundt Cevira.
Om E24 hegnar etc fÄr litt info om dette i blekka, kan det bli moro.
Men som nevnt av andre her, sÄ kan vel ikke DS, snakke sÄ mye om hva Asieris holder pÄ med, desverre.
SÄ fÄr heller hÄpe blÊre butikken gÄr bra 
Full skrivestopp? 
Ssssh
Det er stilhed fĂžr stormen
Bare hemliser som kun deles pÄ insiderchat
1 Like
Ny uke, nye muligheter.
Vi nĂŠrmer oss en avklaring uke for uke , i mellomtiden blir det Q presentasjon!
FÄr vi mulighet til Ä fÄ vite nÄr Asieris har sendt inn sin respons? Det er jo litt lettere Ä beregne tid for sannsynlig avklaring fra myndighetene, om vi i det minste vet nÄr Asieris har sendt inn sitt svar.
FÄr kanskje vite mer pÄ torsdag nÄr Asieris har Q1 Call.
Ellers er det bare Ă„ lete her: https://www.cde.org.cn/main/xxgk/listpage/369ac7cfeb67c6000c33f85e6f374044
Det er en egen fane for Supplementary Information Task Announced, men finner ikke noe for Cevira der enda.
3 Likes
APL-1702 is the first in the world, the first in China, and with the support of high-level clinical evidence. It is expected to become the worldâs first HSIL non-invasive therapy product that has been verified internationally in phase III clinically and has a definite therapeutic effect. Experts believe that under the new population situation in China, the onset of the disease tends to be younger and the treatment status status based on cervical resection surgery bring new challenges to the management of cervical precancerous lesions in the important window period of âfertility protectionâ. APL-1702 is expected to fill this clinical treatment gap and help the construction of fertility friendliness.
In order to better promote the commercialization of APL-1702, the company has successfully held 8 expert consultations on key topics such as phase III clinical data of APL-1702, the diagnosis and treatment status of HSIL, and clinical needs, which has won the innovation of gynecology experts and pharmaceutical experts on APL-1702 and Recognition of clinical value. At the same time, the company has also made substantial progress in seeking strategic cooperation between government departments and relevant academic associations. The company cooperated with the China Cancer Foundation to promote the first real-life exhibition of the innovative prevention and control system for accelerating the elimination of cervical cancer. At the 7th China International Import Expo, it also cooperated with the China Womenâs Development Foundation and China at the Expo. The Cancer Foundation has signed a medium- and long-term strategic cooperation agreement, which is expected to be launched in 2025.
In addition, through extensive market and industry research, the Womenâs Health Division has conducted an in-depth analysis of the needs of doctors and patients and the commercial environment of the industry, and has completed the formulation of key listing strategies and commercialization path planning to ensure that the products can be quickly put on the market after approval.
In view of the relative shortage of innovative drugs in the field of gynecology, APL-1702 is particularly important as a rare breakthrough innovative product with clinical evidence and accurate therapeutic effect in the field of gynecology. In the future, the company will continue to focus on the APL-1702 and the photodynamic pharmaceutical machine joint platform, and plan to build a gynecological product line with gradient and depth in an all-round way with product iteration and indication expansion as the center, supplemented by product collaborative expansion.
4 Likes
Kor er denne teksten frÄ?
Asieris